Details emerge on Cidara/J&J influenza partnership, with a countdown on next steps
Cidara has finally given more details on its influenza deal with Johnson and Johnson’s Janssen after the partnered candidate was removed from the pharma giant’s pipeline last month.
Some details have come out since late July. But San Diego-based Cidara, in its second-quarter earnings announcement Thursday, is now giving a more complete picture of its flu deal.
The company noted that its influenza candidate CD388 — also referred to as JNJ-0953 — was no longer displayed in Janssen’s pipeline as of July 20. It’s a part of Janssen’s plans to discontinue internal development of several infectious disease candidates, including JNJ-0953.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.